Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,changeToNetincome,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,currency,epsCurrentYear,market,shortName,exchange,marketState,priceHint,preMarketChange,preMarketChangePercent,preMarketTime,preMarketPrice,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,exchangeDataDelayedBy,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Apr 29, 2021) 4","Short Ratio (Apr 29, 2021) 4","Short % of Float (Apr 29, 2021) 4","Short % of Shares Outstanding (Apr 29, 2021) 4","Shares Short (prior month Mar 30, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,INMB,47048000,14932600,2491000,,-4556000,,-4556000,2061000,4000,-4548000,-4548000,,,,,,0,4000,4552000,0,-8000,,-4556000,-4556000,16514000,101466000,2312000,63562000,591000,65874000,15000,-37931000,12000,45340000,2196000,12000,147000,49213000,2344000,1572000,30000,28464000,-1465000,28464000,23373000,1000,-5092000,899000,47017000,en-US,US,EQUITY,True,Nasdaq Real Time Price,23.87,1630526402,0.15000153,23.47,24.57,23.31,1162320,-14.466667,2.875,18.203714,5.6662865,0.3112709,15.555326,8.314674,0.53452265,356441184,-12.116752,8.302609,15,America/New_York,EDT,False,False,USD,-1.65,us_market,INmune Bio Inc.,NCM,PRE,2,2.5699997,10.766651,1630574174,26.44,0.6323842,23.31 - 24.57,23.72,0.0,0.0,31,8,finmb_530336663,NasdaqCM,"INmune Bio, Inc.",USD,457831,412514,16.59,2.278846,7.28 - 29.99,-6.119999,-0.20406799,7.28,29.99,1620217800,1620217800,0,1620217800,-1.009,-1.97,-14400000,2.73,,,29.99,7.28,18.2,15.56,457.83k,412.51k,14.93M,,8.89M,40.59%,13.56%,795.02k,4.8,8.94%,5.32%,544.25k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-98,442.46%",-20.50%,-33.93%,14.92k,0.00,,10.92k,,-14.59M,-1.01,,45.34M,3.04,139k,0.22,22.41,2.88,-13M,-7.6M,Value,92037,Healthcare,5,"INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in La Jolla, California.",La Jolla,858 964 3720,CA,1609372800,United States,http://www.inmunebio.com,86400,1200 Prospect Street,Biotechnology,Suite 525
t-1,INMB,22239388,14932600,1858785,,-3204286,,-3204286,1360991,10916,-3208860,-3208860,,,,,,0,10916,3219776,0,4574,,-3204286,-3204286,16514000,72104539,1902548,38753388,190612,40655936,13481,-33375340,10708,21966883,1776262,10708,156214,23985722,1798749,1518113,351559,28464000,-242924,28464000,-2344270,48443,-2392713,702938,22209460,en-US,US,EQUITY,True,Nasdaq Real Time Price,23.87,1630526402,0.15000153,23.47,24.57,23.31,1162320,-14.466667,2.875,18.203714,5.6662865,0.3112709,15.555326,8.314674,0.53452265,356441184,-12.116752,8.302609,15,America/New_York,EDT,False,False,USD,-1.65,us_market,INmune Bio Inc.,NCM,PRE,2,2.5699997,10.766651,1630574174,26.44,0.6323842,23.31 - 24.57,23.72,0.0,0.0,31,8,finmb_530336663,NasdaqCM,"INmune Bio, Inc.",USD,457831,412514,16.59,2.278846,7.28 - 29.99,-6.119999,-0.20406799,7.28,29.99,1620217800,1620217800,0,1620217800,-1.009,-1.97,-14400000,2.73,,,29.99,7.28,18.2,15.56,457.83k,412.51k,14.93M,,8.89M,40.59%,13.56%,795.02k,4.8,8.94%,5.32%,544.25k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-98,442.46%",-20.50%,-33.93%,14.92k,0.00,,10.92k,,-14.59M,-1.01,,45.34M,3.04,139k,0.22,22.41,2.88,-13M,-7.6M,Value,92037,Healthcare,5,"INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in La Jolla, California.",La Jolla,858 964 3720,CA,1609372800,United States,http://www.inmunebio.com,86400,1200 Prospect Street,Biotechnology,Suite 525
t-2,INMB,24692293,14932600,2362880,,-4716662,,-4716662,2456266,0,-4819146,-4819146,,,,,,0,0,4819146,0,102484,,-4716662,-4716662,16514000,71351634,1610153,41206293,253709,42816446,13448,-30171054,12265,24311153,1474110,12265,165388,26137058,1609034,1191086,351763,23240292,-378596,23240292,19494592,-47861,-3697839,1045656,24662948,en-US,US,EQUITY,True,Nasdaq Real Time Price,23.87,1630526402,0.15000153,23.47,24.57,23.31,1162320,-14.466667,2.875,18.203714,5.6662865,0.3112709,15.555326,8.314674,0.53452265,356441184,-12.116752,8.302609,15,America/New_York,EDT,False,False,USD,-1.65,us_market,INmune Bio Inc.,NCM,PRE,2,2.5699997,10.766651,1630574174,26.44,0.6323842,23.31 - 24.57,23.72,0.0,0.0,31,8,finmb_530336663,NasdaqCM,"INmune Bio, Inc.",USD,457831,412514,16.59,2.278846,7.28 - 29.99,-6.119999,-0.20406799,7.28,29.99,1620217800,1620217800,0,1620217800,-1.009,-1.97,-14400000,2.73,,,29.99,7.28,18.2,15.56,457.83k,412.51k,14.93M,,8.89M,40.59%,13.56%,795.02k,4.8,8.94%,5.32%,544.25k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-98,442.46%",-20.50%,-33.93%,14.92k,0.00,,10.92k,,-14.59M,-1.01,,45.34M,3.04,139k,0.22,22.41,2.88,-13M,-7.6M,Value,92037,Healthcare,5,"INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in La Jolla, California.",La Jolla,858 964 3720,CA,1609372800,United States,http://www.inmunebio.com,86400,1200 Prospect Street,Biotechnology,Suite 525
t-3,INMB,5170868,14932600,903043,,-2107804,,-2107804,1204366,0,-2107409,-2107409,,,,,,0,0,2107409,0,-395,,-2107804,-2107804,16514000,47068236,1362677,21684868,361842,23047545,10898,-25454392,60126,4816561,1217247,60126,174649,6358896,1199843,624893,-250084,664845,-142015,664845,-1113975,39378,-1818198,681705,5141649,en-US,US,EQUITY,True,Nasdaq Real Time Price,23.87,1630526402,0.15000153,23.47,24.57,23.31,1162320,-14.466667,2.875,18.203714,5.6662865,0.3112709,15.555326,8.314674,0.53452265,356441184,-12.116752,8.302609,15,America/New_York,EDT,False,False,USD,-1.65,us_market,INmune Bio Inc.,NCM,PRE,2,2.5699997,10.766651,1630574174,26.44,0.6323842,23.31 - 24.57,23.72,0.0,0.0,31,8,finmb_530336663,NasdaqCM,"INmune Bio, Inc.",USD,457831,412514,16.59,2.278846,7.28 - 29.99,-6.119999,-0.20406799,7.28,29.99,1620217800,1620217800,0,1620217800,-1.009,-1.97,-14400000,2.73,,,29.99,7.28,18.2,15.56,457.83k,412.51k,14.93M,,8.89M,40.59%,13.56%,795.02k,4.8,8.94%,5.32%,544.25k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-98,442.46%",-20.50%,-33.93%,14.92k,0.00,,10.92k,,-14.59M,-1.01,,45.34M,3.04,139k,0.22,22.41,2.88,-13M,-7.6M,Value,92037,Healthcare,5,"INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in La Jolla, California.",La Jolla,858 964 3720,CA,1609372800,United States,http://www.inmunebio.com,86400,1200 Prospect Street,Biotechnology,Suite 525
